Payment overview · 2025
General Payments
$288.99
13 reported records · 9 companies
Healthcare provider profile · identity verified
Laura Heringer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DEMOREST, GA · NPI 1912140278
Verified facts
What the public records show
CMS Open Payments records show Laura Heringer, MD received $288.99 in general payments during 2025 across 13 reported records.
Eisai Inc. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $54.40 | 18.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $41.93 | 14.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.55 | 14.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.27 | 13.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.65 | 11.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.02 | 7.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.00 | 7.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.56 | 6.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.61 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.99 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $54.40 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $41.93 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.65 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 193 |
| Lisinopril | Lisinopril | 430 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 118 |
| Losartan Potassium | Losartan Potassium | 309 | 96 |
| Sertraline Hcl | Sertraline Hcl | 275 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 96 |
| Omeprazole | Omeprazole | 263 | 93 |
| Gabapentin | Gabapentin | 242 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 58 |
| Trazodone Hcl | Trazodone Hcl | 174 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 52 |
| Famotidine | Famotidine | 166 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 48 |
| Tramadol Hcl | Tramadol Hcl | 150 | 33 |
| Potassium Chloride | Potassium Chloride | 149 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 40 |
| Alendronate Sodium | Alendronate Sodium | 125 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 39 |
| Furosemide | Furosemide | 122 | 40 |
| Metformin Hcl | Metformin Hcl | 121 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 61 |
| Ozempic | Semaglutide | 108 | 35 |
| Chlorthalidone | Chlorthalidone | 107 | 43 |
| Montelukast Sodium | Montelukast Sodium | 105 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 27 |
| Simvastatin | Simvastatin | 92 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 50 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 25 |
| Ezetimibe | Ezetimibe | 84 | 32 |
| Carvedilol | Carvedilol | 81 | 24 |
| Bupropion Xl | Bupropion Hcl | 80 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 29 |
| Metformin Hcl Er | Metformin Hcl | 76 | 29 |
| Buspirone Hcl | Buspirone Hcl | 74 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 22 |
| Clonazepam | Clonazepam | 70 | 14 |
| Estradiol | Estradiol | 70 | 31 |
| Eliquis | Apixaban | 69 | 17 |
| Finasteride | Finasteride | 69 | 21 |
| Propranolol Hcl | Propranolol Hcl | 67 | 26 |
| Allopurinol | Allopurinol | 66 | 18 |
| Glipizide | Glipizide | 62 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 16 |
| Pregabalin | Pregabalin | 60 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Meloxicam | Meloxicam | 55 | 22 |
| Memantine Hcl | Memantine Hcl | 55 | 21 |
| Mirtazapine | Mirtazapine | 55 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 20 |
| Spironolactone | Spironolactone | 53 | 17 |
| Atenolol | Atenolol | 50 | 14 |
| Donepezil Hcl | Donepezil Hcl | 50 | 20 |
| Alprazolam | Alprazolam | 49 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 11 |
| Benazepril Hcl | Benazepril Hcl | 46 | 13 |
| Ondansetron Odt | Ondansetron | 46 | 28 |
| Prednisone | Prednisone | 46 | 32 |
| Cephalexin | Cephalexin | 44 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Mounjaro | Tirzepatide | 36 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 14 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Mupirocin | Mupirocin | 31 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 12 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | 11 |
| Torsemide | Torsemide | 29 | 11 |
| Acyclovir | Acyclovir | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 18 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Azithromycin | Azithromycin | 19 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 12 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Klor-Con-Ef | Potassium Bicarbonate/Cit Ac | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $288.99 · 13 records | Eisai Inc. | JOURNAVX, Leqembi, MOUNJARO, NUPLAZID, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Tymlos, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error